Pipeline

PIPELINE

Genetically-Engineered TIL Therapies

We are developing a novel class of genetically-engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform.

CoStAR-TIL
Candidate Indication Discovery IND-Enabling Phase 1 Phase 2/3
ITIL-306 NSCLC, Ovarian, RCC
Multiple Undisclosed

NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma;